AxoGen, Inc (NASDAQ:AXGN) – Jefferies Financial Group issued their Q1 2020 earnings per share estimates for AxoGen in a research report issued to clients and investors on Wednesday, November 6th, Zacks Investment Research reports. Jefferies Financial Group analyst R. Denhoy anticipates that the medical equipment provider will post earnings of ($0.13) per share for the quarter. Jefferies Financial Group also issued estimates for AxoGen’s Q2 2020 earnings at ($0.10) EPS.
Other research analysts have also recently issued research reports about the company. William Blair cut AxoGen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 7th. Cantor Fitzgerald decreased their target price on AxoGen from $30.00 to $21.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. BTIG Research decreased their target price on AxoGen to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th. Canaccord Genuity set a $30.00 target price on AxoGen and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, BidaskClub raised AxoGen from a “strong sell” rating to a “sell” rating in a research note on Monday, November 25th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $25.00.
Hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC boosted its stake in shares of AxoGen by 9,583.9% during the third quarter. Parallel Advisors LLC now owns 3,002 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 2,971 shares in the last quarter. Advisor Group Inc. boosted its stake in shares of AxoGen by 86.3% during the second quarter. Advisor Group Inc. now owns 2,548 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 1,180 shares in the last quarter. Stonebridge Capital Advisors LLC acquired a new stake in shares of AxoGen during the second quarter valued at about $59,000. Synovus Financial Corp acquired a new stake in shares of AxoGen during the third quarter valued at about $66,000. Finally, Aperio Group LLC acquired a new stake in shares of AxoGen during the second quarter valued at about $77,000. 83.58% of the stock is currently owned by hedge funds and other institutional investors.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Featured Article: What is the Gross Domestic Product (GDP)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.